Unknown PHASE3 INTERVENTIONAL NCT00022178

Combination Chemotherapy in Treating Patients With Metastatic Cancer of an Unknown Site of Origin

An Open Label Prospective Randomised Study Comparing The Use Of Vincristine, Adriamycin And Cyclophosphamide (VAC) Versus Epirubicin, Cisplatin And Continuous 5-Flourouracil (ECF) In Patients With Unknown Primary Carcinoma (UPC)

Sponsor: The Christie NHS Foundation Trust

Conditions Carcinoma of Unknown Primary

Interventions cisplatin cyclophosphamide doxorubicin hydrochloride epirubicin hydrochloride fluorouracil vincristine sulfate

Updated 5 times since 2017 Last updated: Sep 19, 2013 Started: Dec 31, 1998

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00022178, this PHASE3 trial focuses on Carcinoma of Unknown Primary and remains ongoing. Sponsored by The Christie NHS Foundation Trust, it has been updated 5 times since 1998, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE3
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE3

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE3
Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE3
Jan 2017 — Jun 2018 [monthly]

Unknown Status PHASE3

First recorded

Dec 1998

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

The Christie NHS Foundation Trust

Data source: National Cancer Institute (NCI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Manchester, United Kingdom